Randomized phase III KEYNOTE-045 trial of pembrolizumab versus paclitaxel, docetaxel, or vinflunine in recurrent advanced urothelial cancer: results of >2 years of follow-up
一项随机III期KEYNOTE-045试验比较了帕博利珠单抗与紫杉醇、多西他赛或长春氟宁治疗复发性晚期尿路上皮癌的疗效:超过2年的随访结果
期刊:Annals of Oncology
影响因子:65.4
doi:10.1093/annonc/mdz127
Fradet, Y; Bellmunt, J; Vaughn, D J; Lee, J L; Fong, L; Vogelzang, N J; Climent, M A; Petrylak, D P; Choueiri, T K; Necchi, A; Gerritsen, W; Gurney, H; Quinn, D I; Culine, S; Sternberg, C N; Nam, K; Frenkl, T L; Perini, R F; de Wit, R; Bajorin, D F